FDA Approved: NUCALA — Original Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approves the original application for NUCALA (mepolizumab) by GlaxoSmithKline, for add-on maintenance treatment in patients with severe eosinophilic asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Asthma

Drugs mentioned

• Nucala (mepolizumab)

Snippet

ORIG AP for NUCALA (MEPOLIZUMAB)